Not surprisingly, the COVID-19 pandemic exerted a pronounced chilling effect on M&A activity in the diagnostic space as both buyers and sellers adopted a wait-and-see attitude. But the decline in … [Read more...]
M&A Review
2020 M&A Year in Review: Deal Making Was Low in Volume but High in Impact
January 10, 2021
M&A Report
CompuGroup Medical Makes Major LIS Play by Acquiring Schuyler House
January 10, 2021
It seems fitting that the pandemic year of 2020 should end not with a bang but a whimper. December was the slowest month in M&A deal making of not only this year but many years in recent memory … [Read more...]
M&A Report
Look for Health Care Mergers and Acquisitions to Resurge in 2021
December 2, 2020
Last year at this time, the expectation was that 2020 would be an unusually active year for health care mergers and acquisitions. But the pandemic forced deal makers to shelve their plans and await … [Read more...]
M&A Report
Exact Sciences Makes a Bold Double Play to Bolster Its Early Cancer Detection Capabilities
November 5, 2020
Although volume was light, October was a robust month for M&A deal making in terms of impact, especially in the cancer diagnostics space. The month started with the announcement of Invitae’s … [Read more...]
M&A Report
Re-Acquisition of Grail to Boost Illumina’s Cancer Presence, but Investors Are Skeptical
October 21, 2020
M&A activity during the time of COVID-19 has been notable for two and largely incongruous characteristics: scant numbers of overall deals and unexpected, rather curious blockbusters. A month after … [Read more...]
M&A Report
Surging Demand for COVID-19 Testing Forces Thermo Fisher to Raise Its Offer for Qiagen
August 7, 2020
Back in March, Thermo Fisher Scientific announced that it had agreed to acquire Qiagen for $11.5 billion. At the time, the €39 (roughly $46) per share representing a premium of 23 percent over the … [Read more...]
Diagnostics Deals
3M and MIT Team Up to Create Rapid, Scalable SARS-CoV-2 Antigen Test
August 7, 2020
Unlike reverse transcription-polymerase chain reaction (PCR) and blood-based serology antibody assays, antigen tests are relatively inexpensive to produce and generate results rapidly at the point of … [Read more...]
M&A Report
Invitae-ArcherDX Merger to Create Precision Oncology Powerhouse
July 17, 2020
While M&A deal volume remains abnormally low, business is expected to pick up this summer as the reopening process gets into high gear. Meanwhile, a few new deals are being made, including … [Read more...]
M&A Report
Thermo Fisher Acquisition of Qiagen Remains on Track
June 8, 2020
COVID-19 continues to cast a pall on strategic M&A activity in the diagnostics space with the key players monitoring events before making their moves. However, there are still a few smaller deals … [Read more...]
Diagnostic Deals
Labs, Universities and Even Computer Companies Target Point-of-Care COVID-19 Test Development
April 1, 2020
The imperative to create and provide tests capable of detecting the SARS-CoV-2 virus that causes COVID-19 coronavirus continues to fuel strategic deal making. SARS-CoV-2 point-of-care tests was the … [Read more...]
